Inhibikase Therapeutics, Inc. (IKT)
Market Cap | 66.83M |
Revenue (ttm) | 802,425 |
Net Income (ttm) | -4.53M |
Shares Out | 10.05M |
EPS (ttm) | -0.45 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 25 |
Last Price | $6.70 |
Previous Close | $6.60 |
Change ($) | 0.10 |
Change (%) | 1.52% |
Day's Open | 6.89 |
Day's Range | 6.57 - 6.86 |
Day's Volume | 90,308 |
52-Week Range | 6.53 - 9.90 |
ATLANTA, Jan. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and rela...
ATLANTA, Dec. 28, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase"), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and r...
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related...
Eight SPACs went public this past week but no IPOs, as all three scheduled deals postponed or withdrew. New filing activity picked up, led by long-awaited delivery service unicorn DoorDash (DA...
Inhibikase Therapeutics, a clinical stage biotech developing kinase inhibitors for Parkinson's and related disorders, lowered the proposed deal size for its upcoming IPO on Tuesday. The Atlant...
Inhibikase Files Registration Statement for Proposed Initial Public Offering - read this article along with other careers information, tips and advice on BioSpace
About IKT
Inhibikase Therapeutics, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It offers products comprise IkT-01427, a product candidate... [Read more...]
Industry Biotechnology | IPO Date Dec 23, 2020 |
CEO Milton H. Werner | Employees 2 |
Stock Exchange NASDAQ | Ticker Symbol IKT |
Financial Performance
In 2019, IKT's revenue was $1.12 million, a decrease of -72.22% compared to the previous year's $4.04 million. Losses were -$5.72 million, 165.9% more than in 2018.